Tech Company Financing Transactions
Tune Therapeutics Funding Round
On 12/3/2021, Tune Therapeutics raised $40 million in funding from Emerson Collective, New Enterprise Associates and Hatteras Venture Partners.
Transaction Overview
Company Name
Announced On
12/3/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Emerson Collective (Lead Investor)
New Enterprise Associates (Lead Investor)
Proceeds Purpose
This financing will enable Tune to rapidly advance its preclinical research, attract top-tier talent, and further develop its therapeutic platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1616 Eastlake Ave. East
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
Tune Therapeutics, Inc. is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment. With its versatile and powerful TEMPO epigenomic control platform, Tune's experienced team is pioneering a new therapeutic modality that can fine-tune any gene network.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Kane
Chief Scientific Officer
Charles Gersbach
Co-Founder
Fyodor Urnov
Executive Vice President
Heidi Zhang
President
Akira Matsuno
VP - R & D
Blythe Sather
Browse more venture capital transactions:
Prev: 12/3/2021: Goalsetter venture capital transaction
Next: 12/3/2021: Structure venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs